Correlation Between Cullinan Oncology and Prometheus Biosciences

Can any of the company-specific risk be diversified away by investing in both Cullinan Oncology and Prometheus Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cullinan Oncology and Prometheus Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cullinan Oncology LLC and Prometheus Biosciences, you can compare the effects of market volatilities on Cullinan Oncology and Prometheus Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cullinan Oncology with a short position of Prometheus Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cullinan Oncology and Prometheus Biosciences.

Diversification Opportunities for Cullinan Oncology and Prometheus Biosciences

-0.68

Correlation Coefficient

Cullinan Oncology  Prometheus Biosciences

Excellent diversification

The 3 months correlation between Cullinan and Prometheus is -0.68. Overlapping area represents the amount of risk that can be diversified away by holding Cullinan Oncology LLC and Prometheus Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Prometheus Biosciences and Cullinan Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cullinan Oncology LLC are associated (or correlated) with Prometheus Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Prometheus Biosciences has no effect on the direction of Cullinan Oncology i.e., Cullinan Oncology and Prometheus Biosciences go up and down completely randomly.

Pair Corralation between Cullinan Oncology and Prometheus Biosciences

If you would invest  19,992  in Prometheus Biosciences on September 4, 2024 and sell it today you would earn a total of  0.00  from holding Prometheus Biosciences or generate 0.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	1.59%
Values	Daily Returns

Cullinan Oncology LLC  vs.  Prometheus Biosciences

Cullinan Oncology LLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cullinan Oncology LLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Prometheus Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Prometheus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Prometheus Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Cullinan Oncology and Prometheus Biosciences

The main advantage of trading using opposite Cullinan Oncology and Prometheus Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cullinan Oncology position performs unexpectedly, Prometheus Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prometheus Biosciences will offset losses from the drop in Prometheus Biosciences' long position.

The idea behind Cullinan Oncology LLC and Prometheus Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.